- Home
- LVTX vs AEON Comparison
LVTX vs AEON Comparison
Compare LVTX & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- AEON
- Stock Information
- Founded
- LVTX 2016
- AEON N/A
- Country
- LVTX Netherlands
- AEON United States
- Employees
- LVTX N/A
- AEON N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- AEON Biotechnology: Pharmaceutical Preparations
- Sector
- LVTX Health Care
- AEON Health Care
- Exchange
- LVTX Nasdaq
- AEON Nasdaq
- Market Cap
- LVTX 45.2M
- AEON 38.4M
- IPO Year
- LVTX 2021
- AEON N/A
- Fundamental
- Price
- LVTX $1.74
- AEON $0.99
- Analyst Decision
- LVTX Strong Buy
- AEON Strong Buy
- Analyst Count
- LVTX 2
- AEON 1
- Target Price
- LVTX $6.00
- AEON $5.00
- AVG Volume (30 Days)
- LVTX 28.6K
- AEON 202.7K
- Earning Date
- LVTX 11-14-2024
- AEON 11-11-2024
- Dividend Yield
- LVTX N/A
- AEON N/A
- EPS Growth
- LVTX N/A
- AEON N/A
- EPS
- LVTX N/A
- AEON 0.99
- Revenue
- LVTX $7,398,000.00
- AEON N/A
- Revenue This Year
- LVTX N/A
- AEON N/A
- Revenue Next Year
- LVTX N/A
- AEON N/A
- P/E Ratio
- LVTX N/A
- AEON $0.99
- Revenue Growth
- LVTX N/A
- AEON N/A
- 52 Week Low
- LVTX $1.13
- AEON $0.64
- 52 Week High
- LVTX $6.47
- AEON $17.17
- Technical
- Relative Strength Index (RSI)
- LVTX 57.20
- AEON 50.88
- Support Level
- LVTX $1.56
- AEON $1.01
- Resistance Level
- LVTX $1.78
- AEON $1.11
- Average True Range (ATR)
- LVTX 0.07
- AEON 0.14
- MACD
- LVTX 0.02
- AEON -0.01
- Stochastic Oscillator
- LVTX 81.82
- AEON 11.20
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.